WO2007027273A1 - Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique - Google Patents

Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique Download PDF

Info

Publication number
WO2007027273A1
WO2007027273A1 PCT/US2006/023695 US2006023695W WO2007027273A1 WO 2007027273 A1 WO2007027273 A1 WO 2007027273A1 US 2006023695 W US2006023695 W US 2006023695W WO 2007027273 A1 WO2007027273 A1 WO 2007027273A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
less
ziprasidone
release
particles
Prior art date
Application number
PCT/US2006/023695
Other languages
English (en)
Inventor
John Devane
Paul Stark
Niall Fanning
Gurvinder Rekhi
Scott Jenkins
Gary Liversidge
Original Assignee
Elan Pharma International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/372,857 external-priority patent/US20060240105A1/en
Priority to MX2007016151A priority Critical patent/MX2007016151A/es
Priority to BRPI0612297-3A priority patent/BRPI0612297A2/pt
Priority to EP06773467A priority patent/EP1901722A4/fr
Priority to CA002613474A priority patent/CA2613474A1/fr
Priority to JP2008518266A priority patent/JP2008546781A/ja
Application filed by Elan Pharma International Limited filed Critical Elan Pharma International Limited
Priority to EA200800092A priority patent/EA200800092A1/ru
Priority to AU2006285349A priority patent/AU2006285349A1/en
Publication of WO2007027273A1 publication Critical patent/WO2007027273A1/fr
Priority to IL188093A priority patent/IL188093A0/en
Priority to NO20076628A priority patent/NO20076628L/no
Priority to HK08110215A priority patent/HK1117060A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

  • Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds
  • the present invention relates to compositions that are useful for the prevention and treatment of schizophrenia and similar psychiatric disorders.
  • the present invention relates to compositions comprising an aryl-heterocyclic pharmaceutical compound, for example, ziprasidone.
  • the composition is in nanoparticulate form and comprises also at least one surface stabilizer.
  • the present invention relates also to novel dosage forms for the controlled delivery of an aryl-heterocyclic pharmaceutical compound, for example, ziprasidone and to methods for the prevention and treatment of schizophrenia and similar psychiatric disorders.
  • Ziprasidone chemically known as 5-[2-[4-(l,2-benzisothiazol-3-yl)-l-piper- azinyl]ethyl]-6-chloro-l,3-dihydro-2H-indol-2-one, is a benzothiazolylpiperazine derivative that is used as an antipsychotic agent to treat psychiatric conditions such as schizophrenia, hallucinations, delusions, hostility and other bipolar disorder without increase of lipids and other blood fats.
  • Ziprasidone has an empirical formula of C 2 i ⁇ 2 iClN 4 OS and molecular weight of 412.94 (free base).
  • ziprasidone The chemical structure of ziprasidone is shown below:
  • Ziprasidone may be administered as part of a dosage form offered under the registered trademark name Geodon ® in the United States by Pfizer Inc. Ziprasidone is present in Geodon ® Capsules in the form of the hydrochloride salt of ziprasidone, 5-(2-(4- (l,2-benzisothiazol-3-yl)piperazinyl)ethyl)-6-chloro-l,3-dihydro-2H-indole-2-one monohydrochloride monohydrate.
  • This salt is a white to slightly pink powder, having a melting point of 300 0 C, an empirical formula Of C 2I H 2I ClN 4 OS-HCl-H 2 O and molecular weight of 467.42.
  • Geodon Capsules are supplied for oral administration in 20 mg, 40 mg, 60 mg and 80 mg capsules.
  • Inactive ingredients within the Geodon ® Capsules include lactose, pre-gelatinized starch and magnesium stearate.
  • General dosing for patients includes oral dosage forms (capsules) for treating schizophrenia in adults dosed at 20 milligrams (mg) twice a day with food. Higher dosages may include dosages of 80 mg twice a day.
  • Geodon ® for Injection contains a lyophilized form of ziprasidone mesylate trihydrate (5-(4-(l,2-benzisothiazol-3- yl)piperazinyl)ethyl)-6-chloro-l,3-dihydro-2H-indole-2-one, methanesulfonate, trihydrate (empirical formula: C 2I H 2 ICIN 4 OS-CH 3 SO 3 H-SH 2 O; molecular weight: 563.09).
  • Geodon ® for Injection is available in a single does vial as ziprasidone mesylate containing 20 mg ziprasidone/mL.
  • Ziprasidone has been approved by the U.S. Food & Drug Administration (FDA) for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients.
  • the elimination half-life of ziprasidone is about 7 hours.
  • Steady state plasma concentrations are achieved within one to three days.
  • the bioavailability of ziprasidone is about 60% when taken with food. It has been reported that about one in twenty patients titrated up to high doses of Geodon ® (360 mg a day) show a significant improvement in cognition.
  • Ziprasidone compounds have been described in U.S. Pat. Nos. 4,831,031; 6,110,918; 6,245,765; 6,150,366; 6,232,304; 6,399,777; and 6,245,766.
  • United States Patent Pub. Nos. 2004/0138237 and 2004/0146562 disclose injectable depot formulations of ziprasidone wherein the active ziprasidone compound is solubilized with a cyclodextrin to form a suspension.
  • Ziprasidone is highly effective in the therapeutic treatment of patients suffering from schizophrenia and similar mental disorders. However, given the need to take ziprasidone two times a day and the further need to take ziprasidone after meals, strict patient compliance is a critical factor in the efficacy of ziprasidone in the treatment of schizophrenia and similar mental disorders. Moreover, such frequent administration often requires the attention of health care workers and contributes to the high cost associated with treatments involving ziprasidone. Thus, there is a need in the art for ziprasidone compositions which overcome these and other problems associated with their use in the treatment of schizophrenia and similar psychoses.
  • One embodiment of the invention encompasses a nanoparticulate composition
  • a nanoparticulate composition comprising: (A) ziprasidone; and (B) at least one surface stabilizer.
  • the surface stabilizer can be adsorbed on or associated with the surface of the nanoparticulate particles.
  • the nanoparticulate particles have an effective average particle size of less than about 2,000 nm.
  • the nanoparticulate composition may optionally comprise one or more additional active ingredients useful in the prevention and treatment of schizophrenia and similar psychiatric disorders and/or one or more pharmaceutically acceptable excipients.
  • the administration of the nanoparticulate composition to a subject in a fed or fasted state may be bioequivalent and may exhibit similar pharmacokinetics.
  • the present invention also relates to modified release composition having a first component comprising a first population of active ingredient-containing particles and at least a second component comprising a second population of active ingredient-containing particles, wherein each component has a different rate and/or duration of release and wherein at least one of said components comprises ziprasidone.
  • the particles of the at least second component are provided in a modified release (MR) form such as, for example, coated with a modified release coating or comprising or incorporated in a modified release matrix material.
  • Such modified release compositions may comprise a nanoparticulate form of ziprasidone and at least one surface stabilizer, and may optionally comprise one or more additional active ingredients useful in the prevention and treatment of schizophrenia and similar psychiatric disorders and/or one or more pharmaceutically acceptable excipients.
  • the first component of the modified release composition may exhibit a variety of release profiles including profiles in which substantially all of the active ingredient contained in the first component is released rapidly upon administration of the dosage form, released rapidly but after a time delay (delayed release), or released slowly over time.
  • the active ingredient contained in the first component of the dosage form is released rapidly upon administration to a patient.
  • released rapidly includes release profiles in which at least about 80% of the active ingredient of a component of the dosage form is released within about an hour after administration
  • delayed release includes release profiles in which the active ingredient of a component of the dosage form is released (rapidly or slowly) after a time delay
  • controlled release includes release profiles in which at least about 80% of the active ingredient contained in a component of the dosage form is released slowly.
  • the second component of the modified release composition may also exhibit a variety of release profiles including an immediate release profile, a delayed release profile or a controlled release profile.
  • the second component exhibits a delayed release profile in which the active ingredient of the component is released after a time delay.
  • the second component exhibits a controlled release profile in which the active ingredient of the component is released over a period of about 12 to about 24 hours after administration.
  • the release profile of the active ingredients from the composition is bimodal.
  • the first component exhibits an immediate release profile and the second component exhibits a delayed release profile
  • the duration of the lag time may be varied by altering the amount and/or composition of the modified release coating or by altering the amount and/or composition of the modified release matrix material utilized to achieve the desired release profile.
  • the duration of the lag time can be designed to mimic a desired plasma profile.
  • the active ingredients in the first and second components are released over different time periods.
  • the immediate release component serves to hasten the onset of action by minimizing the time from administration to a therapeutically effective plasma concentration level, and the one or more subsequent components serve to minimize the variation in plasma concentration levels and/or maintain a therapeutically effective plasma concentration throughout the dosing interval.
  • the active ingredient in the first component is released rapidly and the active ingredient in the second component is released within a period of about 12 hours after administration.
  • the active ingredient in the first component is released rapidly and the active ingredient in the second component is released within a period of about 24 hours after administration.
  • the active ingredient in the first component is released rapidly and the active ingredient in the second component is released over a period of about 12 hours after administration. In still another such embodiment, the active ingredient in the first component is released rapidly and the active ingredient in the second component is released over a period of about 24 hours after administration. In yet another such embodiment, the active ingredient in the first component is released rapidly and the active ingredient in the second component is released over a period of at least about 12 hours after administration. In still another such embodiment, the active ingredient in the first component is released rapidly and the active ingredient in the second component is released over a period of at least about 24 hours after administration.
  • the plasma profile produced by the administration of dosage forms of the present invention which comprise an immediate release component and at least one modified release component can be substantially similar to the plasma profile produced by the administration of two or more IR dosage forms given sequentially, or to the plasma profile produced by the administration of separate IR and MR dosage forms.
  • the modified release composition of the present invention is particularly useful for administering ziprasidone which is normally administered two times daily.
  • the composition delivers the ziprasidone in a bimodal manner. Upon administration, such a composition produces a plasma profile which substantially mimics that obtained by the sequential administration of two IR doses of ziprasidone in accordance with a typical treatment regimen.
  • the composition can be designed to produce a plasma profile that minimizes or eliminates the variations in plasma concentration levels associated with the administration of two or more IR dosage forms given sequentially.
  • the composition may be provided with an immediate release component to hasten the onset of action by minimizing the time from administration to a therapeutically effective plasma concentration level, and at least one modified release component to maintain a therapeutically effective plasma concentration level throughout the dosing interval.
  • the ziprasidone may be contained in nanoparticulate particles which comprise also at least one surface stabilizer.
  • the present invention also relates to dosage forms made from the compositions of the present invention.
  • the dosage form is a solid oral dosage form comprising the modified release composition of the present invention.
  • the oral dosage form may utilize, for example, erodable formulations, diffusion controlled formulations and osmotic controlled formulations.
  • the total dose contained in the dosage form may be release in a pulsatile or continuous manner. In one such embodiment, a portion of the total dose is released immediately to allow for rapid onset of effect, and the remainder of the total dose is release after a lag time or over a period of time up to about 24 hours.
  • the dosage form is an injectable depot formulation comprising a nanoparticulate composition comprising ziprasidone.
  • the depot formulation slowly dissolves and releases the drug into the patient's circulation.
  • a single injection of the formulation can provide effective therapeutic plasma concentrations of ziprasidone for up to 3 months.
  • the present invention is also directed to a method of making a nanoparticulate composition comprising ziprasidone.
  • Such method comprises the step of contacting nanoparticulate particles comprising ziprasidone with at least one surface stabilizer for a period of time and under conditions sufficient to provide a stabilized nanoparticulate composition comprising ziprasidone.
  • the present invention further relates to methods of treatment including but not limited to, the prevention and treatment of schizophrenia and similar mental disorders.
  • Such methods comprise the step of administering to a subject a therapeutically effective amount of a composition, for example, a nanoparticulate composition, comprising ziprasidone.
  • compositions and dosage fo ⁇ ns of the present invention are useful in reducing the required dosing frequency thereby increasing patient convenience and improving patient compliance and, therefore, the therapeutic outcome for all treatments requiring ziprasidone including but not limited to, the prevention and treatment of schizophrenia and similar psychiatric disorders.
  • This approach can replace conventional ziprasidone dosage forms, which are administered multiple times daily.
  • ziprasidone includes ziprasidone, its pharmaceutically acceptable salts, acids, esters, metabolites, complexes or other derivatives and thereof, and each of their respective stereoisomers including mixtures, racemic or otherwise, of two or more such stereoisomers.
  • terapéuticaally effective amount of ziprasidone means the dosage that provides the specific pharmacological response for which the ziprasidone is administered in a significant number of subjects in need of the relevant treatment. It is emphasized that a therapeutically effective amount of ziprasidone that is administered to a particular subject in a particular instance will not always be effective in treating the conditions described herein, even though such dosage is deemed to be a therapeutically effective amount by those of skill in the art.
  • pill refers to a state of matter which is characterized by the presence of discrete particles, pellets, beads or granules irrespective of their size, shape or morphology.
  • multiparticulate means a plurality of discrete, or aggregated, particles, pellets, beads, granules or mixture thereof irrespective of their size, shape or morphology.
  • a composition comprising a multiparticulate is described herein as a “multiparticulate composition.”
  • nanoparticulate refers to a multiparticulate in which the effective average particle size of the particles therein is less than about 2000 nm (2 microns) in diameter.
  • a composition comprising a nanoparticulate is described herein as a “nanoparticulate composition.”
  • effective average particle size to describe a multiparticulate (e.g., a nanoparticulate) means that at least 50% of the particles thereof are of a specified size. Accordingly, "effective average particle size of less than about 2000 nm in diameter” means that at least 50% of the particles therein are less than about 2000 nm in diameter.
  • D50 refers to the particle size below which 50% of the particles in a multiparticulate fall.
  • D90 refers to the particle size below which 90% of the particles in a multiparticulate fall.
  • stable refers to, but is not limited to, one or more of the following parameters: (1) the particles do not appreciably flocculate or agglomerate due to interparticle attractive forces or otherwise significantly increase in particle size over time; (2) the physical structure of the particles is not altered over time, such as by conversion from an amorphous phase to a crystalline phase; (3) the particles are chemically stable; and/or (4) where the active ingredient has not been subject to a heating step at or above the melting point of the particles in the preparation of the nanoparticles of the present invention.
  • “poorly water soluble drug” refers to a drug that has a solubility in water of less than about 30 mg/ml, less than about 20 mg/ml, less than about 10 mg/ml, or less than about 1 mg/ml.
  • modified release includes a release which is not immediate and includes controlled release, extended release, sustained release and delayed release.
  • time delay refers to the period of time between the administration of a dosage form comprising the composition of the invention and the release of the active ingredient from a particular component thereof.
  • lag time refers to the time between the release of the active ingredient from one component of the composition and the release of the active ingredient from another component of the composition.
  • electrode refers to formulations which may be worn away, diminished, or deteriorated by the action of substances within the body.
  • diffusion controlled refers to formulations which may spread as the result of their spontaneous movement, for example, from a region of higher to one of lower concentration.
  • osmotic controlled refers to formulations which may spread as the result of their movement through a semi-permeable membrane into a solution of higher concentration that tends to equalize the concentrations of the formulation on the two sides of the membrane.
  • the present invention provides a nanoparticulate composition
  • a nanoparticulate composition comprising particles which comprise: (A) ziprasidone, or a salt or derivative thereof; and (B) at least one surface stabilizer.
  • Nanoparticulate compositions were first described in U.S. Patent No.
  • Nanoparticulate active agent compositions are described also in, for example,
  • the effective average particle size of the particles in the nanoparticulate composition of the present invention is less than about 2000 nm (i.e., 2 microns) in diameter.
  • the effective average particle size may be, for example, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm in
  • the nanoparticulate particles may exist in a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi amorphous phase, or a mixture thereof.
  • the nanoparticulate composition of the present invention exhibits increased bioavailability, and requires smaller doses of the ziprasidone as compared to prior conventional, non-nanoparticulate compositions which comprise ziprasidone.
  • the nanoparticulate composition of the present invention has a bioavailability that is about 50% greater than ziprasidone administered in a conventional dosage form.
  • the nanoparticulate composition of the present invention has a bioavailability that is about 40% greater, about 30% greater, about 20% or about 10% greater than ziprasidone administered in a conventional dosage form.
  • the nanoparticulate composition may also have a desirable pharmacokinetic profile as measured following the initial dosage thereof to a mammalian subject.
  • the desirable pharmacokinetic profile of the composition includes, but is not limited to: (1) a C m a x for ziprasidone when assayed in the plasma of a mammalian subject following administration that is preferably greater than the C max for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition; and/or (2) an AUC for ziprasidone when assayed in the plasma of a mammalian subject following administration that is preferably greater than the AUC for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition; and/or (3) a T max for ziprasidone when assayed in the plasma of a mammalian subject following administration that is preferably less than the T max for the same ziprasidone delivered at the same dosage by a non- nanoparticulate composition.
  • a nanoparticulate composition of the present invention exhibits, for example, a T ma ⁇ for ziprasidone contained therein which is not greater than about 90% of the T max for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition.
  • the nanoparticulate composition of the present invention may exhibit, for example, a T max for ziprasidone contained therein which is not greater than about 80%, not greater than about 70%, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not greater than about 15%, not greater than about 10%, or not greater than about 5% of the T m a x for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition.
  • the T max of ziprasidone when assayed in the plasma of the mammalian subject is less than about 6 to about 8 hours after administration.
  • the T max of ziprasidone is less than about 6 hours, less than about 5 hours, less than about 4 hours, less than about 3 hours, less than about 2 hours, less than about 1 hour, or less than about 30 minutes after administration.
  • a nanoparticulate composition of the present invention exhibits, for example, a C max for ziprasidone contained therein which is at least about 50% of the C max for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition.
  • the nanoparticulate composition of the present invention may exhibit, for example, a C max for ziprasidone contained therein which is at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700%, at least about 800%, at least about 900%, at least about 1000%, at least about 1100%, at least about 1200%, at least about 1300%, at least about 1400%, at least about 1500%, at least about 1600%, at least about 1700%, at least about 1800%, or at least about 1900% greater than the C max for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition.
  • a C max for ziprasidone contained therein which is at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700%, at least about 800%, at least about 900%, at least about 1000%, at least about 1100%
  • a nanoparticulate composition of the present invention exhibits, for example, an AUC for ziprasidone contained therein which is at least about 25% greater than the AUC for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition.
  • the nanoparticulate composition of the present invention may exhibit, for example, an AUC for ziprasidone contained therein which is at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about 550%, at least about 600%, at least about 750%, at least about 700%, at least about 750%, at least about 800%, at least about 850%, at least about 900%, at least about 950%, at least about 1000%, at least about 1050%, at least about 1100%, at least about 1150%, or at least about 1200% greater than the AUC for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition.
  • an AUC for ziprasidone contained therein which is at least about 50%, at
  • the invention encompasses a nanoparticulate composition wherein the pharmacokinetic profile of ziprasidone following administration is not substantially affected by the fed or fasted state of a subject ingesting the composition. This means that there is no substantial difference in the quantity of ziprasidone absorbed or the rate of absorption when the nanoparticulate composition is administered in the fed versus the fasted state.
  • conventional ziprasidone formulations i.e., Geodon
  • the absorption of ziprasidone is increased when administered with food. This difference in absorption observed with conventional ziprasidone formulations is undesirable.
  • the composition of the invention overcomes this problem.
  • Benefits of a dosage form which substantially eliminates the effect of food include an increase in subject convenience, thereby increasing subject compliance, as the subject does not need to ensure that they are taking a dose either with or without food. This is significant as, with poor subject compliance, an increase in the medical condition for which the ziprasidone is being prescribed may be observed.
  • the invention encompasses also a nanoparticulate composition comprising ziprasidone in which administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state.
  • the difference in absorption of the composition of the invention, when administered in the fed versus the fasted state, preferably is less than about 100%, less than bout 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
  • the invention encompasses a composition comprising ziprasidone wherein the administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, in particular as defined by C max and AUC guidelines given by the U.S. Food and Drag Administration and the corresponding European regulatory agency (EMEA).
  • EMEA European regulatory agency
  • two products or methods are bioequivalent if the 90% Confidence Intervals (CI) for AUC and C max are between 0.80 to 1.25 (T max measurements are not relevant to bioequivalence for regulatory purposes).
  • the 90% CI for AUC must be between 0.80 to 1.25 and the 90% CI for C max must between 0.70 to 1.43.
  • the nanoparticulate composition of the invention is proposed to have an unexpectedly dramatic dissolution profile. Rapid dissolution of ziprasidone is preferable, as faster dissolution generally leads to faster onset of action and greater bioavailability. To improve the dissolution profile and bioavailability of the ziprasidone, it would be useful to increase the drug's dissolution so that it could attain a level close to 100%.
  • compositions of the invention preferably have a dissolution profile in which within about 5 minutes at least about 20% of the ziprasidone is dissolved. In other embodiments of the invention, at least about 30% or at least about 40% of the ziprasidone is dissolved within about 5 minutes. In yet other embodiments of the invention, preferably at least about 40%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the ziprasidone is dissolved within about 10 minutes. Finally, in another embodiment of the invention, preferably at least about 70%, at least about 80%, at least about 90%, or at least about 100% of the ziprasidone is dissolved within about 20 minutes.
  • Dissolution is preferably measured in a medium which is discriminating. Such a dissolution medium will produce two very different dissolution curves for two products having very different dissolution profiles in gastric juices; i.e., the dissolution medium is predictive of in vivo dissolution of a composition.
  • An exemplary dissolution medium is an aqueous medium containing the surfactant sodium lauryl sulfate at 0.025 M. Determination of the amount dissolved can be carried out by spectrophotometry. The rotating blade method (European Pharmacopoeia) can be used to measure dissolution.
  • An additional feature of the nanoparticulate composition of the invention is that particles thereof redisperse so that the particles have an effective average particle size of less than about 2000 nm in diameter. This is significant because, if the particles did not redisperse so that they have an effective average particle size of less than about 2000 nm in diameter, the composition may lose the benefits afforded by formulating the ziprasidone therein into a nanoparticulate fo ⁇ n. This is because nanoparticulate compositions benefit from the small size of the particles comprising the ziprasidone.
  • the particles do not redisperse into small particle sizes upon administration, then "clumps" or agglomerated particles are formed, owing to the extremely high surface free energy of the nanoparticulate system and the thermodynamic driving force to achieve an overall reduction in free energy. With the formation of such agglomerated particles, the bioavailability of the dosage form may fall well below that observed with the liquid dispersion form of the nanoparticulate composition.
  • the redispersed particles of the invention (redispersed in water, a biorelevant media, or any other suitable liquid media) have an effective average particle size of less than about less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm in diameter, as measured by light-scattering methods, microscopy
  • the nanoparticulate composition of the present invention exhibits dramatic redispersion of the particles upon administration to a mammal, such as a human or animal, as demonstrated by reconstitution/redispersion in a biorelevant aqueous media, such that the effective average particle size of the redispersed particles is less than about 2000 run.
  • a biorelevant aqueous media can be any aqueous media that exhibits the desired ionic strength and pH, which form the basis for the biorelevance of the media.
  • the desired pH and ionic strength are those that are representative of physiological conditions found in the human body.
  • Such biorelevant aqueous media can be, for example, aqueous electrolyte solutions or aqueous solutions of any salt, acid, or base, or a combination thereof, which exhibit the desired pH and ionic strength.
  • Biorelevant pH is well known in the art.
  • the pH ranges from slightly less than 2 (but typically greater than 1) up to 4 or 5.
  • the pH can range from 4 to 6, and in the colon it can range from 6 to 8.
  • Biorelevant ionic strength is also well known in the art. Fasted state gastric fluid has an ionic strength of about 0.1M while fasted state intestinal fluid has an ionic strength of about 0.14. See e.g., Lindahl et al., "Characterization of Fluids from the Stomach and Proximal Jejunum in Men and Women," Pharm. Res., 14 (4): 497-502 (1997).
  • pH and ionic strength of the test solution is more critical than the specific chemical content. Accordingly, appropriate pH and ionic strength values can be obtained through numerous combinations of strong acids, strong bases, salts, single or multiple conjugate acid-base pairs (i.e., weak acids and corresponding salts of that acid), monoprotic and polyprotic electrolytes, etc.
  • electrolyte solutions can be, but are not limited to, HCl solutions, ranging in concentration from about 0.001 to about 0.1 N, and NaCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and mixtures thereof.
  • electrolyte solutions can be, but are not limited to, about 0.1 N HCl or less, about 0.01 N HCl or less, about 0.001 N HCl or less, about 0.1 M NaCl or less, about 0.01 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof.
  • 0.01 M HCl and/or 0.1 M NaCl are most representative of fasted human physiological conditions, owing to the pH and ionic strength conditions of the proximal gastrointestinal tract.
  • Electrolyte concentrations of 0.001 N HCl, 0.01 N HCl, and 0.1 N HCl correspond to pH 3, pH 2, and pH 1 , respectively.
  • a 0.01 N HCl solution simulates typical acidic conditions found in the stomach.
  • a solution of 0.1 M NaCl provides a reasonable approximation of the ionic strength conditions found throughout the body, including the gastrointestinal fluids, although concentrations higher than 0.1 M may be employed to simulate fed conditions within the human GI tract.
  • Exemplary solutions of salts, acids, bases or combinations thereof, which exhibit the desired pH and ionic strength include but are not limited to phosphoric acid/phosphate salts + sodium, potassium and calcium salts of chloride, acetic acid/acetate salts + sodium, potassium and calcium salts of chloride, carbonic acid/bicarbonate salts + sodium, potassium and calcium salts of chloride, and citric acid/citrate salts + sodium, potassium and calcium salts of chloride.
  • the composition comprises also at least one surface stabilizer.
  • the surface stabilizer can be adsorbed on or associated with the surface of the ziprasidone-containing particles.
  • the surface stabilizer adheres on, or associates with, the surface of the particles, but does not react chemically with the particles or with other surface stabilizer molecules.
  • Individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular cross-linkages.
  • the relative amounts of the ziprasidone and surface stabilizer present in the composition of the present invention can vary widely.
  • the optional amount of the individual components can depend, upon, among other things, the particular drug selected, the hydrophilic-lipophilic balance (HLB), melting point, and the surface tension of water solutions of the stabilizer.
  • the concentration of the ziprasidone can vary from about 99.5% to about 0.001%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined weight of the ziprasidone and surface stabilizer(s), not including other excipients.
  • the concentration of the surface stabilizer(s) can vary from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, or from about 10% to about 99.5%, by weight, based on the total combined dry weight of the ziprasidone, or a salt or derivative thereof, and surface stabilizer(s), not including other excipients.
  • the choice of a surface stabilizer(s) for the ziprasidone is non-trivial and required extensive experimentation to realize a desirable formulation. Accordingly, the present invention is directed to the surprising discovery that nanoparticulate compositions comprising ziprasidone can be made.
  • Useful surface stabilizers which can be employed in the invention include, but are not limited to, known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Surface stabilizers include nonionic, anionic, cationic, ionic, and zwitterionic surfactants.
  • surface stabilizers include hydroxypropyl methylcellulose (now known as hypromellose), hydroxypropylcellulose, polyvinylpyrrolidone, sodium lauryl sulfate, dioctylsulfosuccinate, gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens ® such as e.g., Tween 20 ® and Tween 80 ® (ICI Speciality Chemicals)); polyethylene glycol glyco
  • cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate trimethylammoniumbromide bromide (PMMTMABr), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate.
  • cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, Ci 2- isdimethyl hydroxyethyl ammonium chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy) 4 ammonium chloride or bromide, N
  • Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry (Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants: Organic Chemistry, (Marcel Dekker, 1990).
  • Nonpolymeric surface stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NR]R 2 R 3 R 4 ⁇ .
  • benzalkonium chloride a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammoni
  • Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylbenzyl ammonium chloride(Quaterniv ⁇ m- 14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, dimethylaminoethyl- chloride hydrochloride, cysteine hydrochloride, diethanolammom ' um POE (10) oletyl ether phosphate, diethanolammonium POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctade
  • the surface stabilizers are commercially available and/or can be prepared by techniques known in the art. Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 2000).
  • compositions of the invention can comprise, in addition to ziprasidone, one or more compounds useful in treating schizophrenia or similar mental disorders and related conditions.
  • the composition may also be administered in conjunction with such a compound.
  • active compounds preferably include those useful for treatment of bodily conditions such as headaches, fevers, soreness, and other like conditions that are generally occasioned with schizophrenia and similar psychiatric disorders.
  • Such active compounds should be present in a manner, as determined by one skilled in the art, such that they do not interfere with the therapeutic effect of ziprasidone.
  • composition of the present invention may comprise also one or more binding agents, filling agents, diluents, lubricating agents, emulsifying and suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, perfuming agents, and other excipients.
  • excipients are known in the art.
  • prevention of the growth of microorganisms can be ensured by the addition of various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • the composition may comprise also isotonic agents, such as sugars, sodium chloride, and the like and agents for use in delaying the absorption of the injectable pharmaceutical form, such as aluminum monostearate and gelatin.
  • filling agents are lactose monohydrate, lactose anhydrous, and various starches
  • binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel ® PHlOl and Avicel ® PHl 02, microcrystalline cellulose, and silicified microcrystalline cellulose (ProSolv SMCCTM).
  • Suitable lubricants including agents that act on the flowability of the powder to be compressed, are colloidal silicon dioxide, such as Aerosil ® 200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
  • sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
  • sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame.
  • flavoring agents are Magnasweet ® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like.
  • preservatives examples include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride.
  • Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing.
  • examples of diluents include microcrystalline cellulose, such as Avicel ® PHlOl and Avicel ® PH 102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose ® DCL21; dibasic calcium phosphate such as Emcompress ® ; mannitol; starch; sorbitol; sucrose; and glucose.
  • Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross- povidone, sodium starch glycolate, and mixtures thereof.
  • effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate.
  • Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts.
  • Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate.
  • sodium bicarbonate component of the effervescent couple may be present.
  • composition of the present invention may comprise also a carrier, adjuvant, or a vehicle (hereafter, collectively, “carriers”).
  • the nanoparticulate compositions can be made using, for example, milling, homogenization, precipitation, freezing, or template emulsion techniques. Exemplary methods of making nanoparticulate compositions are described in the '684 patent. Methods of making nanoparticulate compositions are described also in U.S. Patent Nos. 5,518,187; 5,718,388; 5,862,999; 5,665,331; 5,662,883; 5,560,932; 5,543,133; 5,534,270; 5,510,118; and 5,470,583.
  • particles comprising ziprasidone are dispersed in a liquid dispersion medium in which the ziprasidone is poorly soluble.
  • Mechanical means are then used in the presence of grinding media to reduce the particle size to the desired effective average particle size.
  • the dispersion medium can be, for example, water, saffiower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol.
  • a preferred dispersion medium is water.
  • the particles can be reduced in size in the presence of at least one surface stabilizer.
  • the particles comprising ziprasidone can be contacted with one or more surface stabilizers after attrition. Other compounds, such as a diluent, can be added to the composition during the size reduction process.
  • Dispersions can be manufactured continuously or in a batch mode. One skilled in the art would understand that it may be the case that, following milling, not all particles may be reduced to the desired size. In such an event, the particles of the desired size may be separated and used in the practice of the present invention.
  • Another method of forming the desired nanoparticulate composition is by microprecipitation.
  • This is a method of preparing stable dispersions of poorly soluble ziprasidone in the presence of surface stabilizer(s) and one or more colloid stability- enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal impurities.
  • Such a method comprises, for example: (1) dissolving ziprasidone in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer; and (3) precipitating the formulation from step (2) using an appropriate non-solvent.
  • the method can be followed by removal of any formed salt, if present, by dialysis or diafiltration and concentration of the dispersion by conventional means.
  • a nanoparticulate composition may be formed also by homogenization.
  • Exemplary homogenization methods are described in U.S. Patent No. 5,510,118, for "Process of Preparing Therapeutic Compositions Containing Nanoparticles.”
  • Such a method comprises dispersing particles comprising ziprasidone in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size to the desired effective average particle size.
  • the particles can be reduced in size in the presence of at least one surface stabilizer.
  • the particles can be contacted with one or more surface stabilizers either before or after attrition.
  • Other compounds, such as a diluent can be added to the composition before, during, or after the size reduction process.
  • Dispersions can be manufactured continuously or in a batch mode.
  • Another method of forming the desired nanoparticulate composition is by spray freezing into liquid (SFL).
  • SFL liquid
  • This technology comprises injecting an organic or organoaqueous solution of ziprasidone and surface stabilizer(s) into a cryogenic liquid, such as liquid nitrogen.
  • the droplets of the drug-containing solution freeze at a rate sufficient to minimize crystallization and particle growth, thus formulating nano- structured particles.
  • the particles can have varying particle morphology.
  • the nitrogen and solvent are removed under conditions that avoid agglomeration or ripening of the particles.
  • ultra rapid freezing may also be used to create equivalent nanostructured particles with greatly enhanced surface area.
  • URF comprises talcing a water-miscible, anhydrous, organic, or organoaqueous solution of ziprasidone and surface stabilizer(s) and applying it onto a cryogenic substrate. The solvent is then removed by means such as lyophilization or atmospheric freeze-drying with the resulting nanostructured particles remaining.
  • Template emulsion creates nano-structured particles with controlled particle size distribution and rapid dissolution performance.
  • the method comprises preparing an oil-in-water emulsion and then swelling it with a non-aqueous solution comprising ziprasidone and surface stabilizer(s).
  • the size distribution of the particles is a direct result of the size of the emulsion droplets prior to loading of the emulsion with the drug.
  • the particle size can be controlled and optimized in this process.
  • solvents and stabilizers emulsion stability is achieved with no or suppressed Ostwald ripening. Subsequently, the solvent and water are removed, and the stabilized nano-structured particles are recovered.
  • Various particle morphologies can be achieved by appropriate control of processing conditions.
  • the invention also provides a method comprising the administration of an effective amount of a nanoparticulate composition comprising ziprasidone.
  • composition of the present invention can be formulated for administration parentally (e.g., intravenous, intramuscular, or subcutaneous), orally (e.g., in solid, liquid, or aerosol form, vaginal), nasally, rectally, ocularly, locally (e.g., in powder, ointment, or drop form), buccally, intracisternally, intraperitoneally, or topically, and the like.
  • parentally e.g., intravenous, intramuscular, or subcutaneous
  • orally e.g., in solid, liquid, or aerosol form, vaginal
  • nasally rectally
  • ocularly e.g., in powder, ointment, or drop form
  • buccally intracisternally, intraperitoneally, or topically, and the like.
  • the nanoparticulate composition can be utilized in solid or liquid dosage formulations, such as liquid dispersions, gels, aerosols, ointments, depots, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release formulations, mixed immediate release and controlled release formulations, etc.
  • Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • aqueous and non-aqueous carriers examples include water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • a coating such as lecithin
  • surfactants for example, by the use of surfactants, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • Solid dosage forms for oral administration include, but are not limited to, tablets, capsules, sachets, lozenges, powders, pills, or granules, and the solid dosage form can be, for example, a fast melt dosage form, controlled release dosage form, lyophilized dosage form, delayed release dosage form, extended release dosage form, pulsatile release dosage form, mixed immediate release and controlled release dosage form, or a combination thereof.
  • a solid dose tablet formulation is preferred.
  • the active agent is admixed with at least one of the following: (a) one or more inert excipients (or carriers), such as sodium citrate or dicalcium phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (c) binders, such as carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (f) solution retarders, such as paraffin; (g) absorption accelerators, such as quaternary ammonium compounds; (h) wetting agents, such as cetyl alcohol and glycerol monostearate; ( ⁇ ) adsorbent
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers.
  • Exemplary emulsif ⁇ ers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • oils such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil
  • glycerol tetrahydrofurfuryl alcohol
  • polyethyleneglycols fatty acid esters of sorbitan, or mixtures of these substances, and the like.
  • a therapeutically effective amount of ziprasidone can be determined empirically. Actual dosage levels of ziprasidone in the nanoparticulate compositions of the invention may be varied to obtain an amount of the drug that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered ziprasidone the desired duration of treatment, and other factors.
  • Dosage unit compositions may contain such amounts of ziprasidone or such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the ziprasidone; the duration of the treatment; active compound used in combination or coincidental with ziprasidone; and like factors well known in the medical arts.
  • the effectiveness of pharmaceutical compounds in the prevention and treatment of disease states depends on a variety of factors including the rate and duration of delivery of the compound from the dosage form to the patient.
  • the combination of delivery rate and duration exhibited by a given dosage form in a patient can be described as its in vivo release profile and, depending on the pharmaceutical compound administered, will be associated with a concentration and duration of the pharmaceutical compound in the blood plasma, referred to as a plasma profile.
  • a plasma profile concentration and duration of the pharmaceutical compound in the blood plasma
  • the release profiles of dosage fo ⁇ ns may exhibit different rates and durations of release and may be continuous or pulsatile.
  • Continuous release profiles include release profiles in which a quantity of one or more pharmaceutical compounds is released continuously throughout the dosing interval at either a constant or variable rate.
  • Pulsatile release profiles include release profiles in which at least two discrete quantities of one or more pharmaceutical compounds are released at different rates and/or over different time frames. For any given pharmaceutical compound or combination of such compounds, the release profile for a given dosage form gives rise to an associated plasma profile in a patient.
  • the release profile of the dosage form as a whole is a combination of the individual release profiles and may be described generally as "multimodal.”
  • the release profile of a two-component dosage form in which each component has a different release profile may described as "bimodal," and the release profile of a three-component dosage form in which each component has a different release profile may described as "trimodal.”
  • the associated plasma profile in a patient may exhibit constant or variable blood plasma concentration levels of the pharmaceutical compounds over the duration of action and may be continuous or pulsatile.
  • Continuous plasma profiles include plasma profiles of all rates and duration which exhibit a single plasma concentration maximum.
  • Pulsatile plasma profiles include plasma profiles in which at least two higher blood plasma concentration levels of pharmaceutical compound are separated by a lower blood plasma concentration level and may be described generally as “multimodal.” Pulsatile plasma profiles exhibiting two peaks may be described as “bimodal” and plasma profiles exhibiting three peaks may be described as “trimodal.” Depending on, at least in part, the pharmacokinetics of the pharmaceutical compounds included in the dosage form as well as the release profiles of the individual components of the dosage form, a multimodal release profile may result in either a continuous or a pulsatile plasma profile upon administration to a patient.
  • the present invention provides a multiparticulate modified release composition which delivers ziprasidone, or nanoparticles containing ziprasidone, in a pulsatile manner.
  • the nanoparticles are of the type described above and comprise also at least one surface stabilizer.
  • the present invention provides a multiparticulate modified release composition which delivers ziprasidone, or nanoparticles containing ziprasidone, in a continuous manner.
  • the nanoparticles are of the type described above and comprise also at least one surface stabilizer.
  • the present invention provides a multiparticulate modified release composition in which a first portion of ziprasidone, or nanoparticles containing ziprasidone, is released immediately upon administration and one or more subsequent portions of ziprasidone, or nanoparticles containing ziprasidone, are released after an initial time delay.
  • the present invention provides solid oral dosage forms for once-daily or twice-daily administration comprising the multiparticulate modified release composition of the present invention.
  • the present invention provides a method for the prevention and/or treatment of schizophrenia and similar psychiatric disorders comprising the administration of a composition of the present invention.
  • the present invention provides a multiparticulate modified release composition in which the particles forming the multiparticulate are nanoparticulate particles of the type described above.
  • the nanoparticulate particles may, as desired, contain a modified release coating and/or a modified release matrix material.
  • a pharmaceutical composition having a first component comprising active ingredient- containing particles, and at least one subsequent component comprising active ingredient- containing particles, each subsequent component having a rate and/or duration of release different from the first component wherein at least one of said components comprises particles containing ziprasidone.
  • ziprasidone- containing particles that form the multiparticulate may themselves contain nanoparticulate particles of the type described above which comprise ziprasidone and also at least one surface stabilizer.
  • nanoparticulate particles of the type described above which comprise ziprasidone and also at least one surface stabilizer themselves are the drug-containing particles of the multiparticulate.
  • the drug-containing particles may be coated with a modified release coating.
  • the drug-containing particles may comprise a modified release matrix material.
  • the composition delivers ziprasidone, or nanoparticles containing ziprasidone, in a pulsatile manner.
  • the first component provides an immediate release of ziprasidone, or nanoparticles containing ziprasidone
  • the one or more subsequent components provide a modified release of ziprasidone, or nanoparticles containing ziprasidone.
  • the immediate release component serves to hasten the onset of action by minimizing the time from administration to a therapeutically effective plasma concentration level, and the one or more subsequent components serve to minimize the variation in plasma concentration levels and/or maintain a therapeutically effective plasma concentration throughout the dosing interval.
  • the modified release coating and/or the modified release matrix material cause a lag time between the release of the active ingredient from the first population of active ingredient-containing particles and the release of the active ingredient from subsequent populations of active ingredient-containing particles.
  • the modified release coating and/or the modified release matrix material causes a lag time between the release of the active ingredient from the different populations of active ingredient-containing particles.
  • the duration of these lag times may be varied by altering the composition and/or the amount of the modified release coating and/or altering the composition and/or amount of modified release matrix material utilized.
  • the duration of the lag time can be designed to mimic a desired plasma profile.
  • the modified release composition of the present invention is particularly useful for administering ziprasidone.
  • the composition can be designed to produce a plasma profile that minimizes or eliminates the variations in plasma concentration levels associated with the administration of two or more IR dosage forms given sequentially.
  • the composition may be provided with an immediate release component to hasten the onset of action by minimizing the time from administration to a therapeutically effective plasma concentration level, and at least one modified release component to maintain a therapeutically effective plasma concentration level throughout the dosing interval.
  • the active ingredients in each component may be the same or different.
  • the composition may comprise components comprising only ziprasidone, or nanoparticles containing the ziprasidone, as the active ingredient.
  • the composition may comprise a first component comprising ziprasidone, or nanoparticles containing ziprasidone, and at least one subsequent component comprising an active ingredient other than the ziprasidone, or nanoparticles containing ziprasidone, suitable for co-administration with ziprasidone, or a first component containing an active ingredient other than ziprasidone, or nanoparticles containing ziprasidone, and at least one subsequent component comprising ziprasidone, or nanoparticles containing ziprasidone.
  • two or more active ingredients may be incorporated into the same component when the active ingredients are compatible with each other.
  • An active ingredient present in one component of the composition may be accompanied by, for example, an enhancer compound or a sensitizer compound in another component of the composition, in order to modify the bioavailability or therapeutic effect thereof.
  • Enhancers refers to a compound which is capable of enhancing the absorption and/or bioavailability of an active ingredient by promoting net transport across the GIT in an animal, such as a human.
  • Enhancers include but are not limited to medium chain fatty acids; salts, esters, ethers and derivatives thereof, including glycerides and triglycerides; non-ionic surfactants such as those that can be prepared by reacting ethylene oxide with a fatty acid, a fatty alcohol, an alkylphenol or a sorbitan or glycerol fatty acid ester; cytochrome P450 inhibitors, P-glycoprotein inhibitors and the like; and mixtures of two or more of these agents.
  • the proportion of ziprasidone contained in each component may be the same or different depending on the desired dosing regime.
  • the ziprasidone present in the first component and in subsequent components may be any amount sufficient to produce a therapeutically effective plasma concentration level.
  • the ziprasidone when applicable, may be present either in the form of one substantially optically pure stereoisomer or as a mixture, racemic or otherwise, of two or more stereoisomers.
  • the ziprasidone is present in the composition in an amount of from about 0.1 to about 500 mg. In another embodiment, the ziprasidone is present in the composition in an amount of from about 1 to about 100 mg.
  • the ziprasidone is present in the first component in an amount of from about 0.5 to about 60 mg. In still another embodiment, the ziprasidone is present in the first component in an amount of from about 2.5 to about 30 mg. If in subsequent components, the ziprasidone is present in amounts within similar ranges to those described for the first component.
  • the time release characteristics for the delivery of ziprasidone from each of the components may be varied by modifying the composition of each component, including modifying any of the excipients and/or coatings which may be present. In particular, the release of ziprasidone may be controlled by changing the composition and/or the amount of the modified release coating on the particles, if such a coating is present.
  • the modified release coating for each of these components may be the same or different.
  • release of the active ingredient may be controlled by the choice and amount of modified release matrix material utilized.
  • the modified release coating may be present, in each component, in any amount that is sufficient to yield the desired delay time for each particular component.
  • the modified release coating may be preset, in each component, in any amount that is sufficient to yield the desired time lag between components.
  • the lag time and/or time delay for the release of ziprasidone from each component may also be varied by modifying the composition of each of the components, including modifying any excipients and coatings which may be present.
  • the first component may be an immediate release component wherein ziprasidone is released immediately upon administration.
  • the first component may be, for example, a time-delayed immediate release component in which ziprasidone is released substantially in its entirety immediately after a time delay.
  • the second and subsequent component may be, for example, a time-delayed immediate release component as just described or, alternatively, a time-delayed sustained release or extended release component in which ziprasidone is released in a controlled fashion over an extended period of time.
  • the exact nature of the plasma concentration curve will be influenced by the combination of all of these factors just described.
  • the lag time between the delivery (and thus also the onset of action) of ziprasidone in each component containing ziprasidone may be controlled by varying the composition and coating (if present) of each of the components.
  • numerous release and plasma profiles may be obtained.
  • the duration of the lag time between the release of ziprasidone from each component and the nature of the release of ziprasidone from each component i.e.
  • the plasma profile may be continuous (i.e., having a single maximum) or pulsatile in which the peaks in the plasma profile may be well separated and clearly defined (e.g. when the lag time is long) or superimposed to a degree (e.g. when the lag time is short).
  • the plasma profile produced from the administration of a single dosage unit comprising the composition of the present invention is advantageous when it is desirable to deliver two or more pulses of active ingredient without the need for administration of two or more dosage units.
  • coating materials suitable for use in the practice of the present invention include but are not limited to polymer coating materials, such as cellulose acetate phthalate, cellulose acetate trimaletate, hydroxy propyl methylcellulose phthalate, polyvinyl acetate phthalate, ammonio methacrylate copolymers such as those sold under the trademark Eudragit RS and RL, poly acrylic acid and poly acrylate and methacrylate copolymers such as those sold under the trademark Eudragit ® S and L, polyvinyl acetaldiethylamino acetate, hydroxypropyl methylcellulose acetate succinate, shellac; hydrogels and gel-forming materials, such as carboxyvinyl polymers, sodium alginate, sodium carmellose, calcium carmellose, sodium carboxymethyl starch, polyvinyl alcohol, hydroxyethyl cellulose, methyl cellulose, gelatin, starch, and
  • polyvinylpyrrolidone mol. wt. ⁇ 10k-360k
  • anionic and cationic hydrogels polyvinyl alcohol having a low acetate residual, a swellable mixture of agar and carboxymethyl cellulose, copolymers of maleic anhydride and styrene, ethylene, propylene or isobutylene, pectin (mol. wt. ⁇ 30k-300k), polysaccharides such as agar, acacia, karaya, tragacanth, algins and guar, polyacrylamides, Polyox ® polyethylene oxides (mol. wt.
  • AquaKeep ® acrylate polymers diesters of polyglucan, crosslinked polyvinyl alcohol and poly N-vinyl-2-pyrrolidone, sodium starch glucolate (e.g. Explotab ; Edward Mandell C. Ltd.); hydrophilic polymers such as polysaccharides, methyl cellulose, sodium or calcium carboxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, nitro cellulose, carboxymethyl cellulose, cellulose ethers, polyethylene oxides (e.g.
  • Polyox ® Union Carbide
  • Eudragit ® Rohm and Haas
  • other acrylic acid derivatives other acrylic acid derivatives
  • sorbitan esters natural gums, lecithins, pectin, alginates, ammonia alginate, sodium, calcium, potassium alginates, propylene glycol alginate, agar, and gums such as arabic, karaya, locust bean, tragacanth, carrageens, guar, xanthan, scleroglucan and mixtures and blends thereof.
  • excipients such as plasticisers, lubricants, solvents and the like may be added to the coating.
  • Suitable plasticisers include for example acetylated monoglycerides; butyl phthalyl butyl glycolate; dibutyl tartrate; diethyl phthalate; dimethyl phthalate; ethyl phthalyl ethyl glycolate; glycerin; propylene glycol; triacetin; citrate; tripropioin; diacetin; dibutyl phthalate; acetyl monoglyceride; polyethylene glycols; castor oil; triethyl citrate; polyhydric alcohols, glycerol, acetate esters, gylcerol triacetate, acetyl triethyl citrate, dibenzyl phthalate, dihexyl phthalate, butyl octyl phthalate, diisononyl phthalate, butyl octyl phthalate, dioctyl azelate, epoxidised tallate, triis
  • modified release component comprises a modified release matrix material
  • any suitable modified release matrix material or suitable combination of modified release matrix materials may be used. Such materials are known to those skilled in the art.
  • modified release matrix material includes hydrophilic polymers, hydrophobic polymers and mixtures thereof which are capable of modifying the release of ziprasidone, or a salt or derivative thereof, dispersed therein in vitro or in vivo.
  • Modified release matrix materials suitable for the practice of the present invention include but are not limited to microcrystalline cellulose, sodium carboxymethylcellulose, hydoxyalkylcelluloses such as hydroxypropylmethylcellulose and hydroxypropylcellulose, polyethylene oxide, alkylcelluloses such as methylcellulose and ethylcellulose, polyethylene glycol, polyvinylpyrrolidone, cellulose acteate, cellulose acetate butyrate, cellulose acteate phthalate, cellulose acteate trimellitate, polyvinylacetate phthalate, polyalkylmethacrylates, polyvinyl acetate and mixture thereof.
  • a modified release composition according to the present invention may be incorporated into any suitable dosage form which facilitates release of the active ingredient in a pulsatile manner.
  • the dosage form comprises a blend of different populations of active ingredient-containing particles which make up the immediate release and the modified release components, the blend being filled into suitable capsules, such as hard or soft gelatin capsules.
  • suitable capsules such as hard or soft gelatin capsules.
  • the different individual populations of active ingredient-containing particles may be compressed (optionally with additional excipients) into mini-tablets which may be subsequently filled into capsules in the appropriate proportions.
  • Another suitable dosage form is that of a multilayer tablet. In this instance the first component of the modified release composition may be compressed into one layer, with the second component being subsequently added as a second layer of the multilayer tablet.
  • the populations of the particles making up the composition of the invention may further be included in rapidly dissolving dosage forms such as an effervescent dosage form or a fast-melt dosage form.
  • the composition comprises at least two components containing ziprasidone: a first component and one or more subsequent components.
  • the first component of the composition may exhibit a variety of release profiles including profiles in which substantially all of the ziprasidone contained in the first component is released rapidly upon administration of the dosage form, released rapidly but after a time delay (delayed release), or released slowly over time.
  • the ziprasidone contained in the first component is released rapidly upon administration to a patient.
  • released rapidly includes release profiles in which at least about 80% of the active ingredient of a component is released within about an hour after administration
  • delayed release includes release profiles in which the active ingredient of a component is released (rapidly or slowly) after a time delay
  • controlled release and extended release include release profiles in which at least about 80% of the active ingredient contained in a component is released slowly.
  • the second component of such embodiment may also exhibit a variety of release profiles including an immediate release profile, a delayed release profile or a controlled release profile.
  • the second component exhibits a delayed release profile in which ziprasidone is released after a time delay.
  • the plasma profile produced by the administration of dosage forms of the present invention which comprise an immediate release component comprising ziprasidone, or nanoparticles containing ziprasidone, and at least one modified release component comprising ziprasidone, or nanoparticles containing ziprasidone, can be substantially similar to the plasma profile produced by the administration of two or more IR dosage forms given sequentially, or to the plasma profile produced by the administration of separate IR and modified release dosage forms. Accordingly, the dosage forms of the present invention can be particularly useful for administering ziprasidone where the maintenance of pharmacokinetic parameters may be desired but is problematic.
  • the composition and the solid oral dosage forms containing the composition release ziprasidone such that substantially all of the ziprasidone contained in the first component is released prior to release of ziprasidone from the at least one subsequent component.
  • the first component comprises an IR component
  • release of ziprasidone from subsequent components may be delayed until substantially all of the ziprasidone contained in the first component has been released, and further delayed until at least a portion of the ziprasidone released from the first component has been cleared from the patient's system.
  • release of the ziprasidone from subsequent components of the composition is substantially, if not completely, delayed for a period of at least about two hours after administration of the composition.
  • the release of ziprasidone from subsequent components of the composition is substantially, if not completely, delayed for a period of at least about four hours after administration of the composition.
  • the present invention also includes various types of modified release systems by which ziprasidone may be delivered in either a pulsatile or continuous manner.
  • These systems include but are not limited to: films with ziprasidone, or nanoparticles containing ziprasidone, in a polymer matrix (monolithic devices); systems in which ziprasidone, or nanoparticles containing ziprasidone, is contained by a polymer (reservoir devices); polymeric colloidal particles or microencapsulates (microparticles, microspheres or nanoparticles) in the form of reservoir and matrix devices; systems in which ziprasidone, or nanoparticles containing ziprasidone, is contained by a polymer which contains a hydrophilic and/or leachable additive e.g., a second polymer, surfactant or plasticizer, etc.
  • a hydrophilic and/or leachable additive e.g., a second polymer, surfactant or plasticizer, etc.
  • ziprasidone release may be osmotically controlled (both reservoir and matrix devices); enteric coatings (ionizable and dissolve at a suitable pH); (soluble) polymers with (covalently) attached pendent ziprasidone molecules and devices where release rate is controlled dynamically: e.g., the osmotic pump.
  • the delivery mechanism of the present invention can control the rate of release of ziprasidone. While some mechanisms will release ziprasidone at a constant rate, others will vary as a function of time depending on factors such as changing concentration gradients or additive leaching leading to porosity, etc.
  • Polymers used in sustained release coatings are necessarily biocompatible, and ideally biodegradable.
  • examples of both naturally occurring polymers such as Aquacoat ® (FMC Corporation, Food & Pharmaceutical Products Division, Philadelphia, USA) (ethylcellulose mechanically spheronised to sub-micron sized, aqueous based, pseudo-latex dispersions), and also synthetic polymers such as the Eudragit ® (Rohm Pharma, Rothstadt.) range of poly(acrylate, methacrylate) copolymers are known in the art.
  • a typical approach to modified release is to encapsulate or contain the drug entirely (e.g., as a core), within a polymer film or coat (i.e., microcapsules or spray/pan coated cores).
  • the rate of release decreases exponentially with time as the concentration (activity) of the agent (i.e., the driving force for release) within the device decreases (i.e., first order release). If, however, the active agent is in a saturated suspension, then the driving force for release is kept constant until the device is no longer saturated.
  • the release-rate kinetics may be desorption controlled, and a function of the square root of time.
  • Transport properties of coated tablets may be enhanced compared to free- polymer films, due to the enclosed nature of the tablet core (permeant) which may enable the internal build-up of an osmotic pressure which will then act to force the permeant out of the tablet.
  • Coated salt tablets shaped as disks, were found to swell in de-ionized water and change shape to an oblate spheroid as a result of the build-up of internal hydrostatic pressure: the change in shape providing a means to measure the force generated.
  • the osmotic force decreased with increasing levels of PEG content.
  • the lower PEG levels allowed water to be imbibed through the hydrated polymer, while the porosity resulting from the coating dissolving at higher levels of PEG content (20 to 40%) allow the pressure to be relieved by the flow of KCl.
  • Monolithic Devices Monolithic (matrix) devices may be used for controlling the release of a drug.
  • the active agent is present as a dispersion within the polymer matrix, and they are typically formed by the compression of a polymer/drug mixture or by dissolution or melting.
  • the dosage release properties of monolithic devices may be dependent upon the solubility of the drug in the polymer matrix or, in the case of porous matrixes, the solubility in the sink solution within the particle's pore network, and also the tortuosity of the network (to a greater extent than the permeability of the film), dependent on whether the drug is dispersed in the polymer or dissolved in the polymer.
  • the drug will be released by a solution-diffusion mechanism (in the absence of pores).
  • the release mechanism will be complicated by the presence of cavities formed near the surface of the device as the drug is lost: such cavities fill with fluid from the environment increasing the rate of release of the drug.
  • plasticizer e.g., a poly(ethylene glycol)
  • a surfactant i.e., an ingredient which increases effectiveness
  • adjuvant i.e., an ingredient which increases effectiveness
  • matrix devices and reservoir devices
  • plasticizers may be fugitive, and simply serve to aid film formation and, hence, decrease permeability - a property normally more desirable in polymer paint coatings.
  • leaching of PEG increased the permeability of (ethyl cellulose) films linearly as a function of PEG loading by increasing the porosity, however, the films retained their barrier properties, not permitting the transport of electrolyte.
  • surfactant may increase the release rate of a drug by three possible mechanisms: (i) increased solubilization, (ii) improved 'wettability' to the dissolution media, and (iii) pore formation as a result of surfactant leaching.
  • Composite devices consisting of a polymer/drug matrix coated in a polymer containing no drug also exist. Such a device was constructed from aqueous Eudragit ® lattices, and was found to provide a continuous release by diffusion of the drug from the core through the shell. Similarly, a polymer core containing the drug has been produced and coated with a shell that was eroded by gastric fluid. The rate of release of the drug was found to be relatively linear (a function of the rate limiting diffusion process through the shell) and inversely proportional to the shell thickness, whereas the release from the core alone was found to decrease with time.
  • Hollow microspheres were formed by preparing a solution of ethanol/dichloromethane containing the drug and polymer. On pouring into water, an emulsion is formed containing the dispersed polymer/drug/solvent particles, by a coacervation-type process from which the ethanol rapidly diffused precipitating polymer at the surface of the droplet to give a hard-shelled particle enclosing the drug dissolved in the dichloromethane. A gas phase of dichloromethane was then generated within the particle which, after diffusing through the shell, was observed to bubble to the surface of the aqueous phase. The hollow sphere, at reduced pressure, then filled with water which could be removed by a period of drying. No drug was found in the water.
  • the matrix-type microspheres were prepared by dissolving the drug and polymer in ethanol. On addition to water, the ethanol diffused from the emulsion droplets to leave a highly porous particle. A suggested use of the microspheres was as floating drug delivery devices for use in the stomach. Pendent devices
  • a means of attaching a range of drags such as analgesics and antidepressants, etc., by means of an ester linkage to poly(acrylate) ester latex particles prepared by aqueous emulsion polymerization has been developed. These lattices, when passed through an ion exchange resin such that the polymer end groups were converted to their strong acid form, could self-catalyze the release of the drug by hydrolysis of the ester link.
  • Drugs have been attached to polymers, and also monomers have been synthesized with a pendent drug attached. Dosage forms have been prepared in which the drug is bound to a biocompatible polymer by a labile chemical bond e.g., polyanhydrides prepared from a substituted anhydride (itself prepared by reacting an acid chloride with the drug: methacryloyl chloride and the sodium salt of methoxy benzoic acid) were used to form a matrix with a second polymer (Eudragit ® RL) which released the drug on hydrolysis in gastric fluid.
  • polyanhydrides prepared from a substituted anhydride (itself prepared by reacting an acid chloride with the drug: methacryloyl chloride and the sodium salt of methoxy benzoic acid) were used to form a matrix with a second polymer (Eudragit ® RL) which released the drug on hydrolysis in gastric fluid.
  • Enteric coatings consist of pH sensitive polymers. Typically the polymers are carboxylated and interact very little with water at low pH, while at high pH the polymers ionize causing swelling or dissolving of the polymer. Coatings can therefore be designed to remain intact in the acidic environment of the stomach, protecting either the drug from this environment or the stomach from the drug, but to dissolve in the more alkaline environment of the intestine.
  • the osmotic pump is similar to a reservoir device but contains an osmotic agent (e.g., the active agent in salt form) which acts to imbibe water from the surrounding medium via a semi-permeable membrane.
  • an osmotic agent e.g., the active agent in salt form
  • Such a device called an elementary osmotic pump, has been described.
  • Pressure is generated within the device which forces the active agent out of the device via an orifice of a size designed to minimize solute diffusion, while preventing the build-up of a hydrostatic pressure head which can have the effect of decreasing the osmotic pressure and changing the dimensions of the device.
  • the internal volume of the device remains constant, and there is an excess of solid or saturated solution in the device, then the release rate remains constant delivering a volume equal to the volume of solvent uptake.
  • Monolithic devices have been prepared using polyelectrolyte gels which swell when, for example, an external electrical stimulus is applied causing a change in pH.
  • the release may be modulated by changes in the applied current to produce a constant or pulsatile release profile.
  • hydrogels find use in a number of biomedical applications such as, for example, soft contact lenses, and various soft implants, and the like.
  • a method for treating a patient suffering from schizophrenia or a similar psychiatric disorder comprising the step of administering a therapeutically effective amount of the composition of the present invention in solid oral dosage form.
  • Advantages of the method of the present invention include a reduction in the dosing frequency required by conventional multiple IR dosage regimes while still maintaining the benefits derived from a pulsatile plasma profile or eliminating or minimizing the variations in plasma concentration levels. This reduced dosing frequency is advantageous in terms of patient compliance and the reduction in dosage frequency made possible by the method of the present invention would contribute to controlling health care costs by reducing the amount of time spent by health care workers on the administration of ziprasidone. In the following examples, all percentages are weight by weight unless otherwise stated.
  • purified water refers to water that has been purified by passing it through a water filtration system. It is to be understood that the examples are for illustrative purposes only, and should not be interpreted as restricting the spirit and breadth of the invention as defined by the scope of the claims that follow.
  • Examples 1 to 4 provide exemplary ziprasidone tablet formulations. These examples are not intended to limit the claims in any respect, but rather to provide exemplary tablet formulations of ziprasidone which can be utilized in the methods of the invention. Such exemplary tablets can also comprise a coating agent.
  • a multiparticulate modified-release composition according to the present invention comprising an immediate release component and a modified-release component containing ziprasidone is prepared as follows.
  • a solution of ziprasidone is prepared according to any of the formulations given in Table 1.
  • the methylphenidate solution is then coated onto nonpareil seeds to a level of approximately 16.9% solids weight gain using, for example, a Glatt GPCG3 (Glatt, Protech Ltd., Leicester, UK) fluid bed coating apparatus to form the IR particles of the immediate release component.
  • Glatt GPCG3 Glatt, Protech Ltd., Leicester, UK
  • Ziprasidone-containing delayed release particles are prepared by coating immediate release particles prepared according to Example 5(a) above with a modified- release coating solution as detailed in Table 2.
  • the immediate release particles are coated to varying levels up to approximately to 30% weight gain using, for example, a fluid bed apparatus.
  • Modified release component coating solutions Amount, % (w/w)
  • Talc is simultaneously applied during coating for formulations in column (i), (iv) and (vi).
  • the immediate and delayed release particles prepared according to Example 5 (a) and (b) above are encapsulated in size 2 hard gelatin capsules to an overall 20 mg dosage strength using, for example, a Bosch GKF 4000S encapsulation apparatus.
  • the overall dosage strength of 20 mg ziprasidone was made up of 10 mg from the immediate release component and 10 mg from the modified-release component.
  • Multiparticulate modified-release ziprasidone compositions according to the present invention having an immediate release component and a modified-release component having a modified-release matrix material are prepared according to the formulations shown in Table 3 (a) and (b). TABLE 3 (a)
  • IR component 100 mg is encapsulated with 100 mg of modified release (MR) component to give a 20 mg dosage strength product
  • nanoparticulate ziprasidone composition may be prepared.
  • An aqueous dispersion of 5% (w/w) ziprasidone, combined with one or more surface stabilizers, such as hydroxypropyl cellulose (HPC-SL) and dioctylsulfosuccinate (DOSS), may be milled in a 10 ml chamber of a NanoMill ® 0.01 (NanoMill Systems, King of Prussia, PA; see e.g., U.S. Patent No. 6,431,478), along with 500 micron PolyMill ® attrition media (Dow Chemical Co.) (e.g., at an 89% media load).
  • the mixture may be milled at a speed of 2500 rpms for 60 minutes.
  • the particle size of the milled ziprasidone particles can be measured, in deionized distilled water, using a Horiba LA 910 particle size analyzer.
  • the initial mean and/or D50 milled ziprasidone particle size is expected to be less than 2000 run.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition comprenant de la ziprasidone utilisée pour le traitement et la prévention de la schizophrénie et de troubles psychiatriques similaires. Dans un mode de réalisation, la composition inclut des nanoparticules comprenant de la ziprasidone et au moins un agent stabilisant de surface. Les nanoparticules ont une taille effective moyenne inférieure à 2000 nm environ. Dans un autre mode de réalisation, la composition comprend une composition de libération modifiée qui, après administration à un patient, délivre la ziprasidone de manière bimodale, multimodale ou continue. L'invention concerne également des formes galéniques contenant de telles compositions et des procédés de traitement et de prévention de la schizophrénie et de troubles psychiatriques similaires.
PCT/US2006/023695 2005-06-20 2006-06-19 Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique WO2007027273A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2006285349A AU2006285349A1 (en) 2005-06-20 2006-06-19 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
BRPI0612297-3A BRPI0612297A2 (pt) 2005-06-20 2006-06-19 composição de nanoparticulado estável, método para prepará-la, uso da mesma, composição farmacêutica, uso da mesma, forma de dosagem, composição de liberação controlada, e, uso da mesma
EP06773467A EP1901722A4 (fr) 2005-06-20 2006-06-19 Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique
CA002613474A CA2613474A1 (fr) 2005-06-20 2006-06-19 Compositions de nanoparticules a liberation controlee comprenant des composes d'aryle heterocyclique
JP2008518266A JP2008546781A (ja) 2005-06-20 2006-06-19 アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
MX2007016151A MX2007016151A (es) 2005-06-20 2006-06-19 Composiciones de liberacion controlada y en forma de nano-particulas que comprenden compuestos aril-heterociclicos.
EA200800092A EA200800092A1 (ru) 2005-06-20 2006-06-19 Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения
IL188093A IL188093A0 (en) 2005-06-20 2007-12-12 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
NO20076628A NO20076628L (no) 2005-06-20 2007-12-21 Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser
HK08110215A HK1117060A1 (en) 2005-06-20 2008-09-16 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69209605P 2005-06-20 2005-06-20
US60/692,096 2005-06-20
US11/372,857 US20060240105A1 (en) 1998-11-02 2006-03-10 Multiparticulate modified release composition
US11/372,857 2006-03-10

Publications (1)

Publication Number Publication Date
WO2007027273A1 true WO2007027273A1 (fr) 2007-03-08

Family

ID=37809174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/023695 WO2007027273A1 (fr) 2005-06-20 2006-06-19 Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique

Country Status (12)

Country Link
EP (1) EP1901722A4 (fr)
KR (1) KR20080024206A (fr)
CN (1) CN101879140A (fr)
AU (1) AU2006285349A1 (fr)
BR (1) BRPI0612297A2 (fr)
CA (1) CA2613474A1 (fr)
EA (1) EA200800092A1 (fr)
HK (1) HK1117060A1 (fr)
IL (1) IL188093A0 (fr)
NO (1) NO20076628L (fr)
SG (1) SG162811A1 (fr)
WO (1) WO2007027273A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109844A1 (fr) * 2008-03-07 2009-09-11 Pfizer Inc. Procédés, formes pharmaceutiques, et nécessaires pour administrer de la ziprasidone sans nourriture
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
WO2010082855A1 (fr) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Compositions pharmaceutiques comprenant de la ziprasidone sous forme de base libre ou de chlorhydrate et leur méthode d'élaboration
WO2011148253A2 (fr) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Formes posologiques solides d'antipsychotiques
WO2015095230A1 (fr) * 2013-12-16 2015-06-25 Massachusetts Institute Of Technology Formulations de vaccin micro-moulées ou imprimées en trois dimensions (3d) à libération pulsatile
US11541017B2 (en) 2013-12-16 2023-01-03 Massachusetts Institute Of Technology Fortified micronutrient salt formulations

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518187A (en) * 1992-11-25 1996-05-21 Nano Systems L.L.C. Method of grinding pharmaceutical substances
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6228398B1 (en) * 1998-11-02 2001-05-08 Elan Corporation, Plc Multiparticulate modified release composition
US20040138237A1 (en) * 2002-10-25 2004-07-15 Pfizer Inc Novel injectable depot formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
ES2191618T3 (es) * 1999-05-27 2003-09-16 Pfizer Prod Inc Suspension de ziprasidona.
JP2007504266A (ja) * 2003-09-02 2007-03-01 ファイザー・プロダクツ・インク ジプラシドンの持続放出剤形
CA2605153A1 (fr) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Formulations de depot injectables et procedes destines a assurer une liberation prolongee de compositions de nanoparticules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518187A (en) * 1992-11-25 1996-05-21 Nano Systems L.L.C. Method of grinding pharmaceutical substances
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6228398B1 (en) * 1998-11-02 2001-05-08 Elan Corporation, Plc Multiparticulate modified release composition
US20040138237A1 (en) * 2002-10-25 2004-07-15 Pfizer Inc Novel injectable depot formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1901722A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109844A1 (fr) * 2008-03-07 2009-09-11 Pfizer Inc. Procédés, formes pharmaceutiques, et nécessaires pour administrer de la ziprasidone sans nourriture
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
WO2010082855A1 (fr) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Compositions pharmaceutiques comprenant de la ziprasidone sous forme de base libre ou de chlorhydrate et leur méthode d'élaboration
WO2011148253A2 (fr) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Formes posologiques solides d'antipsychotiques
WO2015095230A1 (fr) * 2013-12-16 2015-06-25 Massachusetts Institute Of Technology Formulations de vaccin micro-moulées ou imprimées en trois dimensions (3d) à libération pulsatile
AU2014364930B2 (en) * 2013-12-16 2017-06-15 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
US10300136B2 (en) 2013-12-16 2019-05-28 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
US10960073B2 (en) 2013-12-16 2021-03-30 Tokitae Llc Micromolded or 3-D printed pulsatile release vaccine formulations
US11541017B2 (en) 2013-12-16 2023-01-03 Massachusetts Institute Of Technology Fortified micronutrient salt formulations
US11975069B2 (en) 2013-12-16 2024-05-07 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations

Also Published As

Publication number Publication date
NO20076628L (no) 2008-03-12
BRPI0612297A2 (pt) 2010-11-03
IL188093A0 (en) 2008-03-20
CA2613474A1 (fr) 2007-03-08
CN101879140A (zh) 2010-11-10
EA200800092A1 (ru) 2008-06-30
AU2006285349A1 (en) 2007-03-08
KR20080024206A (ko) 2008-03-17
EP1901722A4 (fr) 2011-06-15
SG162811A1 (en) 2010-07-29
HK1117060A1 (en) 2009-01-09
EP1901722A1 (fr) 2008-03-26

Similar Documents

Publication Publication Date Title
US8119163B2 (en) Nanoparticulate and controlled release compositions comprising cefditoren
AU2007260822B2 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US20070160675A1 (en) Nanoparticulate and controlled release compositions comprising a cephalosporin
US20080113025A1 (en) Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20080102121A1 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
EP2032137A2 (fr) Compositions comprenant du naproxène nanoparticulaire et de l'hydrocodone à libération contrôlée
US20090297596A1 (en) Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor
US20090269400A1 (en) Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin
US20080317843A1 (en) Nanoparticulate formulations of modafinil
WO2007027273A1 (fr) Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique
US20110064803A1 (en) Nanoparticulate and controlled release compositions comprising vitamin k2
US20090252807A1 (en) Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives
WO2008073068A1 (fr) Compositions à nanoparticules et à libération contrôlée comprenant du cefditoren
WO2007070082A1 (fr) Nanoparticule et compositions à libération contrôlée qui comprennent une téprénone
US20100247636A1 (en) Nanoparticulate and controlled release compositions comprising nilvadipine
WO2007106111A2 (fr) Compositions nanoparticulaires et a liberation controlee comprenant de la nilvadipine
AU2006343445B8 (en) Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680030232.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006285349

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 188093

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 4857/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/016151

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006773467

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2613474

Country of ref document: CA

Ref document number: 2008518266

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006285349

Country of ref document: AU

Date of ref document: 20060619

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087001338

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200800092

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0612297

Country of ref document: BR

Kind code of ref document: A2